Background-Real-time myocardial contrast echocardiography permits the detection of myocardial perfusion abnormalities during stress echocardiography, which may improve the accuracy of the test in detecting coronary artery stenoses. We hypothesized that this technique could be used after a bolus injection of the selective A2A receptor agonist regadenoson to rapidly and safely detect coronary artery stenoses. Methods and Results-In 100 patients referred for quantitative coronary angiography, real-time myocardial contrast echocardiography was performed during a continuous intravenous infusion of 3% Definity at baseline and at 2-minute intervals for up to 6 minutes after a regadenoson bolus injection (400 g). Myocardial perfusion was assessed by examination of myocardial contrast replenishment after brief high mechanical index impulses. A perfusion defect was defined as a delay (Ͼ2 seconds) in myocardial contrast replenishment in 2 contiguous segments. Wall motion was also analyzed. The overall sensitivity/specificity/accuracy for myocardial perfusion analysis in detecting a Ͼ50% diameter stenosis was 80%/74%/78%, whereas for wall motion analysis it was 60%/72%/66% (PϽ0.001 for differences in sensitivity). Sensitivity for myocardial perfusion analysis was highest on images obtained during the first 2 minutes after regadenoson bolus (PϽ0.001 compared with wall motion), whereas wall motion sensitivity was highest at the 4-to-6 -minute period after the bolus. No significant side effects occurred after regadenoson bolus injection. Conclusions-Regadenoson real-time myocardial contrast echocardiography appears to be a feasible, safe, and rapid noninvasive method for the detection of significant coronary artery stenoses. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT0087369. (Circ Cardiovasc Imaging. 2011;4:628-635.)
C urrent pharmacological myocardial stress perfusion or wall motion imaging protocols require prolonged performance duration because of the time required to achieve an adequate stress state and the additional time needed for acquisition and processing of images. Furthermore, radionuclide imaging protocols involve large doses of radiation to susceptible organs such as the gallbladder, kidney, and upper large intestine. 1, 2 Real-time myocardial contrast echocardiography (RTMCE), using a continuous infusion of ultrasound contrast, has been shown to be effective for detection of myocardial perfusion abnormalities during either vasodilator or demand stress. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Although RTMCE has been used to detect coronary artery stenoses (CAD) with vasodilators such as dipyridamole and adenosine, 10 -13 its use with a direct A2A agonist bolus offers the potential to detect CAD within minutes at the bedside without the need for exposure to ionizing radiation or cumbersome infusion setups. 14, 15 The purpose of the present study was to determine the sensitivity, specificity, and accuracy of RTMCE in the detection of CAD after a regadenoson bolus injection. Second, because bedside assessments of myocardial perfusion can be determined repetitively with RTMCE, we sought to identify the optimal timing for detection of CAD with this technique. study protocol. All patients gave informed consent, and the study was approved by the institutional review boards at the University of Nebraska Medical Center in Omaha, NE, and Mayo Clinic in Rochester, MN. The study was also submitted and approved as an Investigational New Drug (IND) application to the Food and Drug Administration (IND #104,710). Figure 1 demonstrates the total number of patients screened at both institutions, as well as those excluded or who refused to participate in the study. Inclusion criteria were patients scheduled for coronary angiography because of the suspicion of CAD based on symptoms, abnormal stress test, or presence of multiple risk factors for CAD. Exclusion criteria were resting ejection fraction Ͻ40% by biplane echocardiography, New York Heart Association functional class III or IV symptoms, history of high-grade atrioventricular block without pacemaker, use of dipyridamole or caffeine within 24 hours of the stress test, severe reactive airways disease, or reduced life expectancy. Definitions of diabetes, hypertension, and hyperlipidemia were as described previously. 9 The definition of prior coronary artery disease was either by angiography or prior documented myocardial infarction (serial increase in creatine kinase-MB fraction accompanied by chest pain).
Study Protocol and Methods of Analysis
RTMCE was performed with ultrasound scanners equipped with low mechanical index real-time pulse-sequence schemes, which use either interpulse amplitude modulation (power modulation; iE 33; Philips Medical Systems, Bothell, WA) or interpulse phase and amplitude modulation (contrast pulse sequencing; Siemens Acuson Sequoia; Siemens Medical Solutions, Inc, Mountain View, CA). The mechanical index was kept at Յ0.25, and frame rate was kept at 20 to 25 Hz during rest and stress imaging. Time gain compensation and 2-dimensional gain settings were adjusted to suppress any nonlinear signals from tissue before contrast injection. The ultrasound contrast agent infusion for all studies was a 3% dilution of the lipidencapsulated microbubble Definity (Lantheus Medical Imaging, North Billerica, MA) administered at an infusion rate of 3 to 5 mL/min. The infusion rate was adjusted to achieve optimal myocardial opacification without attenuation from within the left ventricular cavity. Brief high mechanical index impulses (1.3 mechanical index for Philips, 1.9 mechanical index for Siemens) were applied, which was sufficient to clear the myocardium of contrast and allow visualization of the timing and degree of myocardial contrast replenishment (MCR).
Perfusion and wall motion were analyzed simultaneously with a 17-segment model. 16 All analyses were performed by an independent reviewer (FX) who was blinded to all clinical and angiographic data. Normal contrast replenishment was defined as a transmural repletion of myocardial contrast that occurred within 4 seconds of the high mechanical index impulse under resting conditions and within 2 seconds after regadenoson stress. Wall motion was assessed by scoring as follows: 1ϭnormal, 2ϭhypokinetic, 3ϭakinetic, and 4ϭdyskinetic. An inducible perfusion defect or wall motion abnormality was one in which a new perfusion defect or wall motion abnormality was evident after regadenoson bolus within at least 2 contiguous segments. A fixed defect was one in which the abnormality (wall motion or perfusion) was present at rest and did not change after the regadenoson bolus. The 17-segment model was divided on a coronary artery territory (CAT) basis into left anterior descending, left circumflex, and right coronary artery perfusion territories as described previously. 6 Of the 19 patients with prior bypass grafting, all had left anterior descending coronary artery (LAD) or diagonal grafts, 16 had circumflex marginal or ramus intermedius grafts, and 13 had right coronary artery (RCA) grafts. Grafts supplying the LAD and diagonal branches were considered LAD territory, whereas grafts supplying the RCA, posterior descending, or posterolateral branches coming off the RCA were assigned to the RCA, and grafts supplying the obtuse marginal were assigned to the left circumflex (LCx) territory. If a bypass graft did not supply the entire territory of the bypassed vessel, and there was still a nonbypassed branch that had a significant stenosis, then that territory was still considered abnormal by angiography.
Perfusion and wall motion images were assessed, as described above, in the apical 4-, 2-, and 3-chamber views at 0 to 2 minutes after the regadenoson bolus and again at 2 to 4 and 4 to 6 minutes after the bolus. Side effects at any time within 1 hour of the regadenoson bolus injection were recorded and included a checklist of those previously reported with regadenoson stress during radionuclide imaging. 17
Semiquantitative Angiography
All patients underwent coronary angiography with multiple projections of the left and right coronary arteries. Semiquantitative analysis of any coronary stenosis was performed independently by an interventional cardiologist (EO) using a standard digital caliper technique, which has correlated well with other quantitative angiographic methods. 18 Comparisons with RTMCE sensitivity and specificity were determined with both a 50% and 70% diameter cutoff.
Statistical Analysis
The primary aim of the study was to estimate the sensitivity and specificity of RTMCE to detect significant coronary artery disease. We anticipated a disease prevalence of 60% using coronary angiography as the reference standard. On the basis of our preliminary data, 19, 20 we anticipated an 85% sensitivity and 80% specificity for RTMCE to detect significant coronary artery disease (defined as at least 1 epicardial vessel or its major branches having a Ͼ50% diameter stenosis). The sample size was estimated with a confidence interval (CI) for a proportion, calculated with NCSS and PASS software. 21 A sample size of 100 produces a 95% CI equal to sensitivity (estimated at 85%) plus or minus 0.07, and a sample size of 100 produces a 95% CI equal to specificity (estimated at 80%) plus or minus 0.08. Together, the individual 95% CIs for sensitivity and specificity provide a joint 90% confidence region for sensitivity and specificity. 22 Comparisons between wall motion and perfusion sensitivity and specificity were performed with a series of 2ϫ2 contingency tables on a patient and CAT basis. A true-positive result, on a patient basis, was defined as the presence of a perfusion defect (fixed or reversible) or wall motion abnormality (fixed or reversible) in any territory and the presence of a Ͼ50% or Ͼ70% coronary stenosis in any vessel at quantitative angiography. 23, 24 All comparisons of sensitivity and specificity values between wall motion and myocardial contrast echocardiography were made with binary data analysis techniques that take into account the correlations of the paired data within patients with PROC GLIMMIX from SAS statistical software, version 9.2 (SAS Institute, Inc, Cary, NC). 
Results
Patient demographics are listed in Table 1 . A total of 34% of patients had diabetes, 48% had a prior percutaneous revascularization or coronary artery bypass grafting, and 29% had a prior myocardial infarction. The indications for coronary angiography were an abnormal dobutamine stress echocardiogram in 14%, abnormal adenosine radionuclide study in 7%, abnormal treadmill stress test in 19%, and high suspicion for CAD (as part of a chest pain, preoperative noncardiac surgery, or valvular heart disease workup) in 60%.
There were no significant adverse side effects noted during the 1-hour observation after the regadenoson bolus injection or Definity contrast infusion. Seven percent of patients complained of chest pain, 48% complained of shortness of breath, and 4% complained of back pain. These symptoms persisted no longer than 5 minutes after the regadenoson bolus. Headaches were reported within 1 hour of regadenoson and Definity administration in 23% of patients. RTMCE perfusion data were not analyzable in 2 patients (total of 6 CATs) because of poor acoustic windows. There were an additional 3 CATs in 3 of the remaining 98 patients in which perfusion was not analyzable.
Angiographic Data
A total of 52 patients (53%) had a Ͼ50% diameter stenosis in at least 1 CAT, whereas 46 patients (47%) had a Ͼ70% diameter stenosis in at least 1 CAT. Multivessel coronary stenoses (with the Ͼ50% diameter cutoff) were present in 31 patients (32%), and single-vessel stenosis was present in 21 (21%). Of the 19 patients with previous CABG, 8 had a Ͼ50% diameter stenosis in at least 1 graft (1 that involved LAD/diagonal grafts, 4 that involved circumflex marginal or ramus intermedius grafts, and 3 that involved RCA grafts).
Real-Time Perfusion Versus Wall Motion for Detection of Coronary Stenoses on a Patient Basis
Of the 98 patients for whom perfusion data could be analyzed, a total of 54 had a perfusion defect in at least 1 CAT after regadenoson, and 45 had a wall motion abnormality (Pϭ0.127). Perfusion defects were inducible in 35 patients, fixed in 12 patients, and fixed and inducible in 7 patients. Patients with fixed defects had corresponding resting wall motion abnormalities in these segments in all cases. Perfusion defects after regadenoson were observed in 1 CAT in 34 patients, whereas perfusion defects in more than 1 CAT were noted in 20 patients. The sensitivity of perfusion analysis for detecting CAD of Ͼ50% severity, on a per patient basis, was 80%, with a specificity of 74%. Perfusion sensitivity was significantly better than wall motion sensitivity (60%; PϽ0.001), whereas specificities were similar ( Table 2 ). The sensitivity of perfusion imaging to detect a Ͼ70% diameter stenosis was also significantly higher than wall motion analysis (PϽ0.001), despite no differences in specificity ( Table 2) .
The sensitivity and specificity of perfusion for detecting multivessel disease (Ͼ50% diameter stenosis in Ͼ1 major epicardial vessel or branch) were 90% and 72%, respectively, whereas for wall motion analysis, they were 75% and 67%, respectively. Figure 2 is an example of an inducible perfusion defect observed in multiple CATs. In the 29 patients with prior myocardial infarction, the sensitivity/specificity/accuracy for the detection of CAD Ͼ50% (on a per patient basis) were 84%/67%/79%, respectively. Table 2 also displays the CAT agreement data. On a CAT basis, the sensitivity/specificity/accuracy of perfusion imaging to detect a Ͼ50% diameter stenosis in the LAD territory was 50%/79%/69%, whereas for the RCA/LCx territory, it was 57%/77%/71%. In the 17 false-negative LAD territories, the RCA or LCx territory was positive in 13 of these (10 true-positives). In the 16 false-negative posterior territories for Ͼ50% stenosis in either the LCx or RCA territories, 8 were positive in the LAD territory (6 true-positives for that territory). True-positives were evident in 8 (50%) of 16 LCx or LAD territories when the RCA territory was read as false-negative and 12 (67%) of 18 RCA or LAD territories when the LCx territory was read as false-negative. Of the 11 patients in whom all 3 CATs were negative for perfusion analysis despite the presence of a Ͼ50% coronary artery stenosis, 7 had single-vessel coronary artery disease, 4 had 2-vessel coronary artery disease, and 1 had multivessel coronary artery disease. There were 5 patients with singlevessel stenosis for whom there was disagreement about which CAT was abnormal by perfusion and which vessel was Ͼ50% stenosed by angiography. CAD indicates coronary artery stenoses; BMI, body mass index; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; and RPP, rate pressure product.
CAT Agreement
Values are percentages or meanϮSD.
A total of 55 coronary stenoses were Ͼ70% in diameter. Sixteen of the territories supplied by this more severe stenosis had a resting perfusion defect, whereas 15 had a resting wall motion abnormality. For detection of a Ͼ70% diameter stenosis, the CAT sensitivity/specificity/accuracy was 51%/ 75%/69% for the LAD territory and 54%/70%/69% for the RCA/LCx territory. Table 3 displays the sensitivity, specificity, and accuracy of perfusion and wall motion for detecting LAD, RCA, or LCx stenoses.
Timing of Perfusion Defects and Wall Motion Abnormalities After Regadenoson
Most perfusion defects were evident on the 0-to-2-minute image acquisition after regadenoson bolus (sensitivity at this stage 78%, specificity 76%). The sensitivity of perfusion analysis was significantly better than wall motion at both the 0-to-2-and 2-to-4 -minute stages after the regadenoson bolus (PϽ0.001) but fell by the 4-to-6 -minute stage (Pϭ0.095 compared with the 0 -2-minute stage), whereas wall motion sensitivity for detecting Ͼ70% diameter stenoses improved during this same time period (Table 3) . Figures 3 and 4 demonstrate examples of end-systolic images obtained at the 0-to-2-, 2-to-4 -, and 4-to-6 -minute stages after the regadenoson bolus injection.
Interobserver Agreement
Interobserver agreement for detection of CAD (nϭ49 patient comparisons) was 76% (ϭ0.50). On a CAT basis, interobserver agreement was 73% for LAD analysis, 73% for RCA analysis, and 77% for LCx analysis. 
Table 2. Comparisons of Sensitivity, Specificity, and Accuracy of Perfusion Versus Wall Motion on a Per Patient and CAT Basis, With Both a 50% and 70% Angiographic Cutoff by Angiography

Discussion
In the present study, we demonstrated that perfusion imaging with regadenoson RTMCE has high sensitivity and specificity for the detection of coronary stenoses. The advantage of RTMCE in this setting is the rapidity with which diagnostic perfusion images could be obtained, while still achieving test sensitivity and specificity equivalent to that of radionuclide imaging. Furthermore, we confirmed the results of previous studies that have shown the tolerability and safety of regadenoson. 14, 15 Hemodynamically, we observed a significant increase in heart rate and a small reduction in systolic and diastolic blood pressure after the regadenoson bolus. These changes, like any of the side effects, were transient, and resolved by 6 minutes after the bolus injection. Therefore, regadenoson RTMCE has the potential to be a rapid, safe bedside stress test to detect CAD that could have multiple clinical applications.
Although previous perfusion studies with regadenoson stress have focused on radionuclide imaging, RTMCE offers several advantages as an imaging technique. First of all, the resolution is improved, which permits the detection of subendocardial defects that may go undetected with radionuclide imaging. 19 Second, the acquisition of MCR data allows the assessment of capillary blood velocity, which permits myocardial blood flow changes to be examined instead of myocardial blood volume. 25, 26 This is critical to the detection of subendocardial blood flow abnormalities, because most defects in the present study were detected during the MCR phase after the high mechanical index impulses. Third, the continuous infusion technique allows perfusion assessments to be made repeatedly, thus reanalyzing both perfusion and wall motion at different time points after the regadenoson injection. This cannot be accomplished with other perfusion imaging techniques and may be valuable in confirming the Table 3 presence of perfusion defects within the first 4 minutes after the regadenoson bolus injection. Finally, there is no need for ionizing radiation. This becomes very important if one anticipates serial perfusion stress testing as a method to follow patients or detect improvements in myocardial blood flow as a result of medical or revascularization therapy. In this context, it is already known that repeated radionuclide testing is both expensive and can result in large cumulative doses of radiation. 2 Ultrasound contrast, on the other hand, has been shown to be safe in thousands of patients, without side effects and with only a very low risk (1 in 15 000) of an anaphylactoid reaction. [27] [28] [29] [30] [31] [32] [33] [34] Although myocardial perfusion was more sensitive than wall motion for detection of CAD, wall motion analysis may also provide some additional information. The segments with induced wall motion abnormalities often persisted even into the 4-to-6 -minute period after the bolus, which indicates that stunning may have occurred, because perfusion at this stage was returning to normal. This may be due to the presence of a more severe coronary obstruction, because the improvement in sensitivity for wall motion in the 4-to-6 -minute period was primarily for detection of Ͼ70% diameter stenoses. Induction of wall motion abnormalities was also helpful for detecting multivessel CAD (sensitivity 75%). These findings indicate that although overall wall motion sensitivity was low, it did assist in the evaluation for the extent and severity of CAD.
. Comparisons of Sensitivity, Specificity, and Accuracy of Perfusion Versus Wall Motion on a Per Patient Basis at 3 Different Time Periods After Regadenoson Bolus
Study Limitations
Ultrasound contrast is not approved by the Food and Drug Administration for perfusion imaging. Nonetheless, the present study, similar to other trials with nonselective adenosine agonists, has demonstrated the additional utility of perfusion imaging in detecting CAD. Although not approved by the Food and Drug Administration, the RTMCE software is available on most Siemens and Philips cardiac ultrasound systems and therefore can be used to both improve endocardial border resolution (the Food and Drug Administrationapproved indication for contrast) and detect myocardial perfusion. This added perfusion information, as demonstrated in the present study, improves the detection of coronary stenoses. Further multicenter investigation is required, however, to rigorously examine whether RTMCE with regadenoson can be effective in detecting CAD in larger patient populations with less experienced investigators.
The ability to detect a stenosis in a given CAT had lower sensitivity than overall patient sensitivity, especially for detecting a Ͼ50 or Ͼ70% diameter stenosis in the LAD territory. Sensitivity was higher on a per patient basis than on a per vessel basis, because in 8 of the 17 false-negatives (47%) of the LAD territories, there was a perfusion defect in the LCx or RCA territory. Similarly, true-positive results were evident in 8 (50%) of 16 LCx or LAD territories when the RCA territory was read as false-negative and 12 (67%) of 18 RCA or LAD territories when the LCx territory was read as false-negative. One reason for this may be that an inducible perfusion defect within a given territory may be more evident when 2-vessel disease is present because of lack of dynamic collateral flow, as has been shown in canine models of stress-induced perfusion defects. 35 Second, the actual segments the stenosed vessel supplied may have been different from what is traditionally ascribed to that vessel. In 5 (38%) of the 13 patients with false-negative studies and singlevessel CAD, an adjacent territory was read as positive (ie, false-positive). Third, more quantitative techniques (other than the visual analysis of replenishment used in the present study) may be required. Although our visual analysis of MCR focused mainly on frames obtained near end systole, a triggered technique that captures images only at end systole may assist in preventing interference from large intramyocardial arterioles, which have been shown to worsen the corre- lation between MCR and myocardial blood flow changes. 36 In addition, quantitative analyses of MCR have been shown to be feasible during vasodilator stress and may improve the detection of stenoses in a particular CAT. 37 Twenty-nine percent of patients in the present study had prior myocardial infarction. Although these patients may be more likely to exhibit fixed perfusion defects and wall motion abnormalities in the absence of a residual stenosis, the sensitivity and specificity of perfusion imaging for detection of coronary stenoses were still 81% and 74% even when these patients were included. However, we did exclude patients with resting ejection fractions Ͻ40% to eliminate patients with more extensive resting regional wall motion abnormalities.
The high prevalence of patients with known CAD in this pilot study must be taken into account when clinical applicability is considered. In other words, the sensitivity and specificity may be different for regadenoson real-time perfusion stress when applied to a chest pain population without known CAD, in whom disease prevalence may be lower. Clearly, multicenter trials in larger numbers of patients with different pretest probabilities will be needed before the accuracy of this test can be determined in specific patient populations.
Although comparisons could be made with other functional imaging techniques, the purpose of the present report was to compare the ability of regadenoson real-time perfusion imaging to detect coronary stenoses of different severity (Ͼ50% and Ͼ70%). Although comparisons with a functional imaging technique may have yielded better correlations, clinical studies assessing the value of functional imaging techniques are almost always compared with angiography. 23, 24 
Conclusions
In this study of 100 patients with preserved systolic function scheduled for coronary angiography at 2 different clinical institutions, myocardial perfusion imaging with RTMCE after a regadenoson bolus injection had good sensitivity and specificity for the detection of patients with CAD. These results were comparable to conventional noninvasive perfusion techniques, but with the advantage of significantly shorter performance time, higher spatial and temporal resolution, and long-term safety advantages. Although ultrasound contrast is only approved for enhancement of left ventricular opacification, RTMCE in this setting could permit the rapid detection of CAD and facilitate patient evaluations of chest pain in a clinical or emergency department setting. Further multicenter studies are required to verify the accuracy of regadenoson RTMCE in the detection of CAD and prediction of patient outcome.
CLINICAL PERSPECTIVE
This study demonstrated that real-time myocardial contrast echocardiography could accurately detect myocardial perfusion abnormalities due to coronary artery disease after a bolus injection of the selective A2A receptor agonist regadenoson. Nearly all perfusion abnormalities could be visualized with real-time myocardial contrast echocardiography within the first 2 minutes of the bolus injection, with higher sensitivity than obtained with wall motion. No significant side effects occurred after regadenoson bolus injection. These findings indicate that regadenoson real-time myocardial contrast echocardiography appears to be a feasible, safe, and rapid noninvasive method for the detection of significant coronary artery stenoses. Unlike radionuclide imaging, no ionizing radiation is required, and the results are available to the physician and patient immediately. Although further multicenter clinical investigation is needed, the use of real-time myocardial contrast echocardiography with regadenoson may be an important alternative pharmacological stress echocardiography test in the future.
